A combination treatment from GlaxoSmithKline for melanoma, the deadliest form of skin cancer, has been delayed in Europe after regulators said they needed more information.
MRV Research
Researcher focuses on advanced melanoma staging, therapies at AAD
Please watch the video by Delphine J. Lee, MD, PhD, FAAD, discussing staging, current therapies and future therapies for advanced melanoma at the American Academy of Dermatology annual meeting
Autophagy inhibition may help overcome BRAF inhibitor resistance in melanoma
Among melanoma patients treated with either BRAF inhibitors or a combination of BRAF and MEK inhibitors, those with higher rates of drug-related autophagy appear to have significantly lower response rates and shorter PFS, according to study results.
Castle Biosciences’ Non-Invasive Gene Expression Profile Test Shown to Identify Sentinel Lymph Node Negative Melanoma Patients at High Risk of…
Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy.